GLYCO-IMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer
GLYCO-IMMUNE CHECKPOINT INHIBITORS
The Need
Despite the early success of first-generation immuno-oncology drugs, most cancer patients still do not achieve clinical responses.
The Scientific Opportunity
Cell surface glycosylation is now known to play a central role in immuno-oncology: Tumor cells evolve over time, cloaking themselves in certain glycan patterns that down-regulate a wide spectrum of innate and adaptive immune cell types which are critical to fighting cancer.
The Approach
Palleon Pharmaceuticals has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glyco-Immune Checkpoint inhibitors to treat cancer patients.
News
Palleon Pharmaceuticals Signs Exclusive License Agreement with King’s College London for Intellectual Property Related to Glycoimmune Checkpoints to Treat Cancer
Twitter
@Palleon_Pharma
Congrats to the winning Palleon team, who out-bowled the competition during our company outing @Kings_dine! Interes… http://tcgTE2Csln
@Palleon_Pharma
Do you want to help lead a new approach in immuno-oncology? Join Palleon, where we're working to harness glyco-immu… http://oq11yi8X7p